Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1338) 1338
science & technology (1236) 1236
life sciences & biomedicine (1222) 1222
male (914) 914
ezetimibe (756) 756
azetidines - administration & dosage (741) 741
female (697) 697
azetidines - therapeutic use (682) 682
middle aged (516) 516
animals (487) 487
biological and medical sciences (469) 469
azetidines - pharmacology (467) 467
medical sciences (453) 453
pharmacology & pharmacy (419) 419
drug therapy, combination (392) 392
aged (390) 390
adult (359) 359
anticholesteremic agents - administration & dosage (345) 345
anticholesteremic agents - therapeutic use (333) 333
treatment outcome (327) 327
azetidines - adverse effects (309) 309
cardiovascular system & cardiology (307) 307
hypercholesterolemia - drug therapy (277) 277
cholesterol, ldl - blood (267) 267
pharmacology. drug treatments (253) 253
administration, oral (236) 236
cholesterol (230) 230
cardiac & cardiovascular systems (229) 229
azetidines - pharmacokinetics (222) 222
abridged index medicus (220) 220
dose-response relationship, drug (214) 214
benzylamines (212) 212
rats (195) 195
simvastatin - administration & dosage (193) 193
double-blind method (191) 191
drug therapy (169) 169
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (165) 165
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (160) 160
general & internal medicine (159) 159
medicine, general & internal (158) 158
statins (156) 156
anticoagulants - therapeutic use (150) 150
mice (149) 149
simvastatin - therapeutic use (141) 141
anticholesteremic agents - adverse effects (137) 137
peripheral vascular disease (137) 137
hypercholesterolemia (134) 134
anticholesteremic agents - pharmacology (132) 132
risk factors (129) 129
cardiology. vascular system (125) 125
simvastatin (125) 125
thrombin - antagonists & inhibitors (123) 123
randomized controlled trials as topic (121) 121
anticoagulants - administration & dosage (119) 119
lipids (119) 119
cardiovascular (118) 118
drug combinations (117) 117
time factors (115) 115
research (113) 113
hypercholesterolemia - blood (110) 110
aged, 80 and over (108) 108
analysis (108) 108
ximelagatran (108) 108
care and treatment (107) 107
clinical trials as topic (105) 105
rats, sprague-dawley (105) 105
atorvastatin calcium (101) 101
adolescent (99) 99
low density lipoproteins (97) 97
cardiovascular disease (96) 96
cholesterol - blood (96) 96
clinical trials (95) 95
azetidines - chemistry (93) 93
antilipemic agents (91) 91
medicine & public health (89) 89
sulfonamides - administration & dosage (88) 88
dosage and administration (87) 87
triglycerides - blood (85) 85
young adult (85) 85
atherosclerosis (84) 84
pyrroles - administration & dosage (82) 82
drug administration schedule (81) 81
hematology (81) 81
sulfonamides - therapeutic use (80) 80
azetidines (79) 79
glycine - analogs & derivatives (79) 79
heptanoic acids - administration & dosage (79) 79
anticoagulants - adverse effects (77) 77
drug interactions (77) 77
pharmacology/toxicology (77) 77
anticoagulants (76) 76
cholesterol, hdl - blood (73) 73
cholesterol, ldl - drug effects (73) 73
coronary heart disease (73) 73
internal medicine (73) 73
anticoagulants - pharmacology (72) 72
cholesterol - metabolism (70) 70
medicine, research & experimental (70) 70
research & experimental medicine (70) 70
hyperlipidemias - drug therapy (69) 69
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1566) 1566
German (37) 37
Japanese (17) 17
French (13) 13
Spanish (11) 11
Hungarian (8) 8
Italian (6) 6
Russian (6) 6
Turkish (5) 5
Czech (4) 4
Danish (3) 3
Portuguese (2) 2
Chinese (1) 1
Dutch (1) 1
Finnish (1) 1
Korean (1) 1
Lithuanian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Effect of evolocumab or ezetimibe added to moderate- Or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial
by Robinson, Jennifer G and Nedergaard, Bettina S and Rogers, William J and Fialkow, Jonathan and Neutel, Joel M and Ramstad, David and Somaratne, Ransi and Legg, Jason C and Nelson, Patric and Scott, Rob and Wasserman, Scott M and Weiss, Robert and LAPLACE-2 Investigators
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 2014, Volume 311, Issue 18, pp. 1870 - 1882
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Dyslipidemias - drug therapy | Double-Blind Method | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Humans | Middle Aged | Ezetimibe | Rosuvastatin Calcium | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Fluorobenzenes - administration & dosage | Hypercholesterolemia - drug therapy | Atorvastatin Calcium | Azetidines - therapeutic use | Pyrroles - administration & dosage | Anticholesteremic Agents - administration & dosage | Heptanoic Acids - administration & dosage | Female | Aged | Drug Therapy, Combination | Sulfonamides - administration & dosage | Side effects | Monoclonal antibodies | Clinical trials | Drug therapy | Low density lipoprotein | Statins | Cholesterol
Journal Article
Details down arrow
2. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis
by Yiu, Zenas Z. N and Warren, Richard B
American journal of clinical dermatology, ISSN 1175-0561, 06/2016, Volume 17, Issue 3, pp. 191 - 200
Life Sciences & Biomedicine | Dermatology | Science & Technology | Humans | Protein Kinase Inhibitors - adverse effects | Thiazoles - adverse effects | Thalidomide - analogs & derivatives | Isonicotinic Acids - administration & dosage | Phosphodiesterase 4 Inhibitors - adverse effects | Pyrroles - administration & dosage | Adenosine - adverse effects | Adamantane - therapeutic use | Pyrroles - adverse effects | Adamantane - administration & dosage | Receptors, Lysosphingolipid - metabolism | Adamantane - analogs & derivatives | Isonicotinic Acids - adverse effects | Thalidomide - adverse effects | Biological Therapy | Isonicotinic Acids - therapeutic use | Piperidines - administration & dosage | Psoriasis - drug therapy | Adenosine A3 Receptor Antagonists - therapeutic use | Administration, Oral | Azetidines - adverse effects | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phosphodiesterase 4 Inhibitors - therapeutic use | Adenosine A3 Receptor Antagonists - adverse effects | Thalidomide - administration & dosage | Adenosine - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Azetidines - therapeutic use | Adenosine - analogs & derivatives | Thalidomide - therapeutic use | Sulfonamides - administration & dosage | Niacinamide - analogs & derivatives | Thiazoles - administration & dosage | Thiazoles - therapeutic use | rho-Associated Kinases - antagonists & inhibitors | Phosphodiesterase 4 Inhibitors - administration & dosage | Adenosine - therapeutic use | Arthritis, Psoriatic - drug therapy | Pyrroles - therapeutic use | Adamantane - adverse effects | Adenosine A3 Receptor Antagonists - administration & dosage | Pyrimidines - administration & dosage | Clinical Trials as Topic | Niacinamide - administration & dosage | Biological Factors - therapeutic use | Janus Kinases - antagonists & inhibitors | Azetidines - administration & dosage | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects
Journal Article
Details down arrow
3. Full Text Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis
by Robertson, Lindsay and Kesteven, Patrick and McCaslin, James E and Robertson, Lindsay
Cochrane library, ISSN 1469-493X, 2015, Volume 2015, Issue 11, pp. CD010956 - CD010956
Pyridines | Anticoagulants | Factor Xa Inhibitors | Administration, Oral | Pyrazoles | Medical treatment | Pyridones | Venous Thrombosis | Deep vein thrombosis | Dabigatran | Randomized Controlled Trials as Topic | Rivaroxaban | Antithrombins | Treatment | Deep vein thrombosis (DVT) related | Thiazoles | Benzylamines | Heart & circulation | Medicine General & Introductory Medical Sciences | Thromboembolism | Azetidines | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Dabigatran - administration & dosage | Pyridines - administration & dosage | Venous Thrombosis - drug therapy | Humans | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Benzylamines - administration & dosage | Rivaroxaban - administration & dosage | Factor Xa Inhibitors - administration & dosage | Pyridones - administration & dosage | Pyrazoles - administration & dosage | Azetidines - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
by Barlow, Ashley and Landolf, Kaitlin M and Barlow, Brooke and Yeung, Siu Yan Amy and Heavner, Jason J and Claassen, Cassidy W and Heavner, Mojdeh S
Pharmacotherapy, ISSN 0277-0008, 05/2020, Volume 40, Issue 5, pp. 416 - 437
dialysis | renal | antivirals | cytochrome P450 | infectious disease | liver | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Pandemics | Alanine - adverse effects | Adrenal Cortex Hormones | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Thiazoles - administration & dosage | Hydroxychloroquine - adverse effects | Thiazoles - adverse effects | Alanine - analogs & derivatives | Alanine - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Ritonavir - adverse effects | Ribavirin - administration & dosage | Betacoronavirus | Antibodies, Monoclonal, Humanized - adverse effects | Ritonavir - administration & dosage | Immunomodulation | Azetidines - adverse effects | Chloroquine - adverse effects | Antiviral Agents - administration & dosage | Adenosine Monophosphate - adverse effects | Hydroxychloroquine - administration & dosage | Nelfinavir - adverse effects | Interferon-alpha - administration & dosage | Azetidines - administration & dosage | Ribavirin - adverse effects | Adenosine Monophosphate - administration & dosage | Adenosine Monophosphate - analogs & derivatives | Antiviral Agents - adverse effects | Coronavirus Infections - therapy | Immunization, Passive | Lopinavir - administration & dosage | Sulfonamides - adverse effects | Chloroquine - administration & dosage | Interferon-alpha - adverse effects | Nelfinavir - administration & dosage | Drug Combinations | Lopinavir - adverse effects | Sulfonamides - administration & dosage | Severe acute respiratory syndrome coronavirus 2 | COVID-19 | Antiviral agents | Therapeutic applications | Clinical trials | Coronaviruses | Drug therapy | Patients | Index Medicus | Reviews of Therapeutics | Review of Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: A randomized trial
by Fiessinger, Jean-Noel and Huisman, Menno V and Davidson, Bruce L and Bounameaux, Henri and Francis, Charles W and Eriksson, Henry and Lundström, Torbjörn and Berkowitz, Scott D and Nyström, Per and Thorsén, Mona and Ginsberg, Jeffrey S and THRIVE Treatment Study Investigato and THRIVE Treatment Study Investigators
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 02/2005, Volume 293, Issue 6, pp. 681 - 689
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Prodrugs - administration & dosage | Recurrence | Anticoagulants - administration & dosage | Humans | Middle Aged | Male | Venous Thrombosis - complications | Heparin, Low-Molecular-Weight - therapeutic use | Warfarin - administration & dosage | Warfarin - therapeutic use | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Pulmonary Embolism - complications | Double-Blind Method | Venous Thrombosis - drug therapy | Venous Thrombosis - mortality | Anticoagulants - therapeutic use | Treatment Outcome | Azetidines - administration & dosage | Azetidines - therapeutic use | Benzylamines | Aged | Prodrugs - therapeutic use | Alanine Transaminase - metabolism | Heparin, Low-Molecular-Weight - administration & dosage | Clinical trials | Cardiac arrhythmia | Thrombolytic drugs | Medical treatment | Blood clots
Journal Article
Details down arrow
6. Full Text Management of Treatment‐Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma
by Daud, Adil and Tsai, Katy
The oncologist (Dayton, Ohio), ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | Life Sciences & Biomedicine | Oncology | Science & Technology | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Index Medicus | Melanoma and Cutaneous Malignancies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)
by Cohen Aubart, Fleur and Emile, Jean-François and Carrat, Fabrice and Charlotte, Frédéric and Benameur, Neila and Donadieu, Jean and Maksud, Philippe and Idbaih, Ahmed and Barete, Stéphane and Hoang-Xuan, Khê and Amoura, Zahir and Haroche, Julien
Blood, ISSN 0006-4971, 09/2017, Volume 130, Issue 11, pp. 1377 - 1380
Life Sciences & Biomedicine | Hematology | Science & Technology | Erdheim-Chester Disease - diagnostic imaging | Follow-Up Studies | Humans | Oximes - administration & dosage | Imidazoles - administration & dosage | Oximes - therapeutic use | Molecular Targeted Therapy | Indoles - administration & dosage | Multicenter Studies as Topic | Registries | Retrospective Studies | Imidazoles - therapeutic use | France | Erdheim-Chester Disease - genetics | Piperidines - administration & dosage | Drug Administration Schedule | Treatment Outcome | Positron Emission Tomography Computed Tomography | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Erdheim-Chester Disease - drug therapy | Azetidines - administration & dosage | Azetidines - therapeutic use | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Indoles - therapeutic use | Sulfonamides - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
by Wang, Faping and Sun, Ling and Wang, Shaohua and Davis, John M and Matteson, Eric L and Murad, M. Hassan and Luo, Fengming and Vassallo, Robert
Mayo Clinic proceedings, ISSN 0025-6196, 07/2020, Volume 95, Issue 7, pp. 1404 - 1419
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Piperidines - administration & dosage | Drug Administration Schedule | Pyrimidines - administration & dosage | Humans | Azetidines - adverse effects | Purines - administration & dosage | Randomized Controlled Trials as Topic | Dose-Response Relationship, Drug | Janus Kinase Inhibitors - adverse effects | Pyrazoles - administration & dosage | Azetidines - administration & dosage | Janus Kinase Inhibitors - administration & dosage | Arthritis, Rheumatoid - drug therapy | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Purines - adverse effects | Sulfonamides - administration & dosage | Pyrazoles - adverse effects | Infection | Complications and side effects | Rheumatoid factor | Tofacitinib | Analysis | Arthritis | Thromboembolism | Cytokines | Pathogenesis | Bias | Rheumatology | Clinical trials | Systematic review | Infections | Patients | Meta-analysis | Studies | Rheumatoid arthritis | Questionnaires | TNF inhibitors | Tumor necrosis factor-TNF | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
by Larkin, James and Ascierto, Paolo A and Dréno, Brigitte and Atkinson, Victoria and Liszkay, Gabriella and Maio, Michele and Mandalà, Mario and Demidov, Lev and Stroyakovskiy, Daniil and Thomas, Luc and de la Cruz-Merino, Luis and Dutriaux, Caroline and Garbe, Claus and Sovak, Mika A and Chang, Ilsung and Choong, Nicholas and Hack, Stephen P and McArthur, Grant A and Ribas, Antoni
The New England journal of medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 20, pp. 1867 - 1876
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Indoles - administration & dosage | Melanoma - genetics | Adult | Female | MAP Kinase Kinase 1 - antagonists & inhibitors | Piperidines - administration & dosage | Azetidines - adverse effects | Kaplan-Meier Estimate | Survival Rate | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Azetidines - administration & dosage | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Aged | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Vemurafenib | Treatment outcome | Usage | Care and treatment | Analysis | Melanoma | Dosage and administration | Drug therapy, Combination | Risk factors | Chemotherapy | Toxicity | MEK inhibitors | Metastasis | Kinases | Survival | Metastases | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights